This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4
Subjects who have never used TNFi, JAKi, or IL-17i drugs before
Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
Subjects who have congenital/traumatic spinal deformities
Subjects currently enrolled in other clinical studies
Subjects who have any contraindications to secukinumab treatment